Cost-Effectiveness Modelling of Sequential Biologic Strategies for the Treatment of Moderate to Severe Rheumatoid Arthritis in Finland by Puolakka, K et al.
38 The  Open  Rheumatology  Journal, 2012, 6, 38-43   
 
  1874-3129/12  2012 Bentham Open 
Open Access 
Cost-Effectiveness Modelling of Sequential Biologic Strategies for the 
Treatment of Moderate to Severe Rheumatoid Arthritis in Finland 
K. Puolakka
1, H. Blåfield
2, M. Kauppi
3, R. Luosujärvi
4, R. Peltomaa
4, T. Leikola-Pelho
5,  
K. Sennfalt
6 and A. Beresniak
*,7,8 
1Lappeenranta Central Hospital, Lappeenranta, Finland 
2Seinäjoki Central Hospital, Seinäjoki, Finland 
3Rheumatism Foundation Hospital, Heinola, Finland 
4Helsinki University Central Hospital, Helsinki, Finland 
5Bristol-Myers Squibb, Helsinki, Finland 
6Bristol-Myers Squibb, Stockholm, Sweden 
7Data Mining International, Geneva, Switzerland 
8Paris-Descartes University, Paris, France 
Abstract: Objective: The main objective was to compare the cost-effectiveness of therapeutic options in moderate or 
severe rheumatoid arthritis (RA) when a clinical response to a first TNF-blocker, either etanercept (ETA), adalimumab 
(ADA), or infliximab (INF), is insufficient. 
Methods: Effectiveness criteria were defined as remission (RS), low disease activity (LDAS), and moderate to high 
disease activity (MHDAS). Cost-effectiveness was derived as cost per day in RS and in LDAS using simulation modelling 
to assess six sequential biologic strategies over 2 years. Each sequential treatment strategy was composed of three 
biologic agents and included a first anti-TNF agent, ETA, ADA or INF, followed by either abatacept (ABA) or rituximab 
(RTX) as a second therapeutic option in case of an insufficient response, followed by another anti-TNF agent in case of 
further insufficient response. 
Results: Over two years and taking into account biologic costs, the following estimated mean costs per day in RS and 
LDAS were respectively of 829 and 428 for the biologic sequence composed of ADA-ABA-ETA, 1292 and 516 for 
the sequence ADA-RTX-ETA, 829 and 429 for the sequence ETA-ABA-ADA, 1292 and 517 for the sequence ETA-
RTX-ADA, 840 and 434 for the sequence INF-ABA-ETA, and 1309 and 523 for the sequence INF-RTX-ETA. 
Conclusion: The treatment sequences including ABA as the second biologic option appear more cost-effective than those 
including RTX in a patients with moderate to severe RA and an insufficient response to a first anti-TNF agent. 
Keywords: Cost-effectiveness, rheumatoid arthritis, biologics, modelling. 
INTRODUCTION 
  Rheumatoid Arthritis (RA) is a common, chronic 
inflammatory disease that produces high rates of morbidity 
and disability, as well as increased mortality, and poses a 
significant challenge and a substantial economic burden both 
on patients and on the healthcare system. According to a 
recent study, the incidence of RA in Finland is 44.5 per 
100’000 individuals over 16 years of age [1]. 
  Therapeutic guidelines recommend that RA treatment be 
initiated with traditional disease-modifying antirheumatic 
drugs (tDMARDs), either with one DMARD or with a 
combination of DMARDs, methotrexate being the “anchor   
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drug” and current standard of care. In case of treatment 
failure to tDMARDs, the new biologic agents (bDMARDs) 
offer further therapeutic treatment options for patients with 
moderate to severe RA. The anti-tumor necrosis factor (anti-
TNF) agents are usually the first bDMARDs to be 
prescribed. In case of an insufficient response to a first anti-
TNF agent, the TNF-inadequate responders (IR) can then 
either be switched to another anti-TNF agent or be treated 
with newer biologic agents abatacept (ABA) or rituximab 
(RTX), both having distinct and different mechanisms of 
action from the anti-TNF agents [2]. 
  Although RA sequential biological treatments represent 
current medical practices, no comparative clinical trials are 
available to assess the clinical efficacy and cost-effectiveness 
of different bDMARDs used in sequence. This may be 
explained by the methodological challenges and the 
prohibitive costs of conducting such complex clinical trials. 
However, using the results from placebo-controlled clinical Cost-Effectiveness of Biologic Therapies in Finland  The Open Rheumatology Journal, 2012, Volume 6   39 
trials for each bDMARDS, decision analytic models can be 
developed and simulation modelling can be used to compare 
different treatment sequences. Such models consist of robust 
mathematic and probabilistic formulas linking published 
clinical evidence and costs in clinical environments 
modelled to reflect local medical practices. This approach is 
aligned with the Outcome Measures in Rheumatology 
Clinical Trials (OMERACT) recommendations [3]. Results 
generated from advanced simulation modelling thus provide 
unique information on the expected effectiveness, overall 
costs, and cost-effectiveness of different biologic strategies 
in order to assist clinical decision-making, as well as 
resource allocation decisions from public health officials. 
  In Finland, biologic agents can be prescribed in patients 
with moderate or severe RA. Hence, the objective of this 
advanced modelling study is to assess the effectiveness, 
costs and cost-effectiveness of different sequential biologic 
treatment strategies for managing moderate to severe RA in 
patients with an insufficient response to a first anti-TNF 
agent in Finland. 
MATERIAL AND METHODOLOGY 
Effectiveness Inputs 
  Two clinically relevant success endpoints were chosen as 
effectiveness criteria [4]. Patients achieving a Disease 
Activity Score (DAS28) <2.6 were defined to be in 
remission state (RS), whereas patients achieving a score 3.2 
were defined to be in low disease activity state (LDAS), and 
those with a score >3.2 were defined to be in moderate to 
high disease activity state (MHDAS). 
  Effectiveness estimates of biological therapies in anti-
TNF inadequate responders were derived directly from 
published clinical trials at the time of model development 
(Tables 1 and 2). Data from randomised controlled clinical 
trials were used if they reported DAS status expressed in 
remission or LDAS rates at 6 months. Thus, the ATTAIN 
trial and long-term extension study were used for ABA [5,6], 
the open label ReAct trial for anti-TNF agents [7] and the 
REFLEX trial and open-label extension analysis for RTX 
[8,9]. The ATTAIN and REFLEX clinical trials were 
deemed comparable in terms of patients baseline 
characteristics (age, gender, disease duration and DAS28 
score at baseline). In absence of published effectiveness data 
for INF or ETA at time of model development, the results of 
the ReAct trial, an open label study [7], were used as best 
surrogate evidence for all anti-TNF agents used as third 
biologic option. This was reinforced by the fact that although 
the ReAct study specifically concerns ADA, the results 
correlate well with those of the Karlsson JA study [10] 
which studied treatment response to anti-TNF switches, 
regardless of the anti-TNF agents used. For the purpose of 
modelling RTX re-treatment intervals, as most patients who 
received additional courses during RTX clinical trials (where 
the need for repeated courses were at physician’s discretion 
based on specific response criteria) did so 24 weeks after the 
previous course, and as none were re-treated sooner than 16 
weeks (RTX US Product monograph), the model set RTX re-
treatment intervals at 6 months in order to sustain a constant 
DAS28 response over time. The data sources are 
summarized in Tables 1 and 2. 
Costs Inputs 
  Resource utilization for these three disease activity states 
(RS, LDAS and MHDAS) was assessed by an expert panel 
of clinical rheumatologists to reflect current medical 
practices in Finland. The panel described ten RA resource 
utilization items: specialist visits, general practionners visits, 
nurse visits, rehabilitation care, laboratory tests, x-ray, 
hospitalization, ortheses (insoles, splints), devices for daily 
activities, and potential household workers. Unit costs from 
the public payer perspective were collected and simulated 
using distribution ranges for each item. Using a specific 
costing model, a computation of all costs distributions was 
performed to estimate the overall direct medical costs over 6 
months. Similar costing methods were used and published 
for other European countries [11]. Biologic drug costs were 
estimated based on the 2009 price lists and recommended 
dosing in Finland. All direct medical costs were estimated 
per 6-month intervals. 
Model Structure 
  Simulation models represent a type of decision trees 
which allow to compute variable distributions. Twelve 
separate models were developed to simulate 6 sequences 
composed of 3 biologic agents using two “success” 
Table 1.  Summary of Effectiveness Probabilities (Percentage of Patients Achieving LDAS) 
 
Biologic Agent    %LDAS  Source 
Abatacept after IR to anti-TNF therapy  Induction -Month 12 
Maintenance 
Month 18 
Month 24 
18.3% 
 
24.2% 
28% 
ATTAIN + LTE study (Genovese 2007) 
 
ATTAIN + LTE study (Genovese 2007) 
ATTAIN + LTE study (Genovese 2007) 
Anti-TNF agents  Induction - Month 18 
Maintenance - Month 24 
11% 
21.5% 
REACT trial (Bombardieri 2007) 
ATTAIN reanalysis afterIR to 2 anti-TNF agents 
Rituximab after IR to anti-TNF therapy  Induction - Month 12 
Maintenance 
Month 18 
Month 24 
13% 
 
25% 
29% 
REFLEX + LTE study (Keystone 2007) 
 
REFLEX + LTE study (Keystone 2007) 
Keystone (EULAR 2007) 
DMARDS  Month 24  5%  Clinical experts opinion 
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endpoints (RS or LDAS)[4,12-14]. In the simulation models 
developed for this study, each new biologic drug introduced 
in the sequence is maintained as long as the clinical response 
is adequate, i.e., achieving at least LDAS. In case of an 
insufficient response, treatment switches are allowed at each 
6-month time points. In order to reflect a population of anti-
TNF inadequate responders, all the sequences assume an 
insufficient response to the first anti-TNF agent appearing in 
each sequence, meaning that the first anti-TNF was not 
efficacious in all patients at the end of the first 6 months. 
The following sequences were modelled accordingly: 
Sequence A: ADA-ABA-ETA; Sequence B: ADA-RTX-
ETA; Sequence C: ETA-ABA-ADA; Sequence D: ETA-
RTX-ADA; Sequence E : INF-ABA-ETA; Sequence F: INF-
RTX-ETA. 
  In sequence A and B, the first anti-TNF is ADA. Hence, 
this means that in sequence A, patients are switched to ABA 
after the first 6-month interval. In case of insufficient 
response to ABA, ETA is then used as the third potential 
biologic agent (Fig. 1). In sequence B, patients are first 
switched to RTX, after which ETA is used in case of an 
insufficient response to RTX. Similarly, sequences C and D 
assume an insufficient response to ETA, after which patients 
are switched to either ABA (sequence C) or RTX (sequence 
D), and further switched to ADA in case of further 
insufficient response to these agents. Sequences E and F 
assume an insufficient response to INF. In sequence E, 
patients are then switched to ABA, and then to ETA in case 
of further insufficient response, while in sequence F, patients 
are switched to RTX, and ultimately to ETA in case of 
further insufficient response. The model assumed that 
patients failing three biologic options would be maintained 
on tDMARDS with a residual effectiveness of achieving RS 
and LDAS estimated at 1% and 5%, respectively. 
  Mean values and standard deviations of the model 
outputs - costs, effectiveness, and mean cost-effectiveness 
over 2 years - were generated by 10’000 Monte-Carlo 
simulations. This approach, also called “probabilistic 
sensitivity analysis”, allows to screen all possible values of a 
given parameter according to its distribution and to 
recalculate the results with standard deviations. Two-group 
means tests with known variances were performed to 
calculate potential significant differences between treatment 
strategies. As no Incremental cost-effectiveness ratio (ICER 
between two strategies = difference in costs / difference in 
effectiveness ) thresholds exist, the results are expressed as 
mean cost-effectiveness values to allow comparisons 
between the different treatment sequences. In this particular 
context, ICERs would otherwise be extremely difficult if not 
impossible to interpret. 
RESULTS 
  Direct medical costs of managing RA in Finland 
(excluding the cost of biological therapies) were estimated at 
527 (SD=123) over 6 months for patients achieving RS, 
2724 (SD=1131) for patients achieving LDAS, and 5600 
(SD=2243) for patients in MHDAS. Hence, achieving LDAS 
or remission was associated with lower medical costs (Fig. 
1). Key costs drivers were hospitalization and medical visits. 
  Costs per day in RS or per day in LDAS, were 
respectively  829 (SD=85) and 428 (SD=45) for the 
biologic sequence A (ADA-ABA-ETA), 1292 (SD=136) 
and 516 (SD=56) for sequence B (ADA-RTX-ETA), 829 
(SD=85) and 429 (SD=46) for sequence C (ETA-ABA-
ADA), 1292 (SD=136) and 517 (SD=56) for sequence D 
(ETA-RTX-ADA), 840 (SD=85) and 434 (SD=45) for the 
sequence E (INF-ABA-ETA), and 1309 (SD=136) and 
523 (SD=56) for sequence F (INF-RTX-ETA). Significant 
differences in cost-effectiveness ratios were observed 
between sequences A and B (p <0.01), C and D (p<0.01), as 
well as E and F (p<0.01) favouring sequences containing 
ABA vs RTX. 
DISCUSSION 
  After taking into account all relevant clinical data and the 
Finnish public health care system perspective and 
constraints, our models generated original results showing 
that sequences including ABA appear more efficacious and 
cost-effective than similar sequences including RTX for 
patients with moderate to severe RA, who have experienced 
insufficient response to a first anti-TNF agent. Our results 
also clearly establish the relation between disease activity 
and medical resources. One of the most important issues in 
the creation of valid medico-economic models is the use of 
clinical effectiveness endpoints that are clinically meaningful 
and consistent across different settings. Selecting objective 
Table 2.  Summary of Effectiveness Probabilities (Percentage of Patients Achieving RS) 
 
Biologic Agent    %RS  Source 
Abatacept after IR to anti-TNF therapy  Induction -Month 12 
Maintenance 
Month 18 
Month 24 
11.1% 
 
13.9% 
17.1% 
ATTAIN + LTE study (Genovese 2007) 
 
ATTAIN + LTE study (Genovese 2007) 
ATTAIN + LTE study (Genovese 2007) 
Anti-TNF agents   Induction - Month 18 
Maintenance - Month 24 
4% 
14.4% 
REACT trial (Bombardieri 2007) 
ATTAIN reanalysis after IR to 2 anti-TNF agents 
Rituximab after IR to anti-TNF therapy  Induction - Month 12 
Maintenance 
Month 18 
Month 24 
6% 
 
13% 
12% 
REFLEX + LTE study (Keystone 2007) 
 
REFLEX + LTE study (Keystone 2007) 
Keystone (EULAR 2007) 
DMARDS  Month 24  1%  Clinical experts opinion 
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and consistent clinical outcomes allow to define clinical 
effectiveness for a given treatment more accurately and to 
compare across different treatment strategies for a specific 
patient population. 
  In lack of head-to-head clinical studies, which would 
allow to compare the clinical efficacy and cost-effectiveness 
of various sequential treatment strategies, modelling such 
comparative studies is an important and valid way to address 
the problem [15]. In particular, creating advanced simulation 
models requires expert validation of clinical assumptions and 
effectiveness endpoints. Achieving a state of remission or 
low disease activity being the therapeutic targets when 
treating RA, dichotomous approaches to effectiveness 
(success/no-success) are clinically meaningful and are 
generally more easily interpreted than continuous measures 
[4]. Success cut-off endpoints are also the standard outcomes 
reported in clinical trials [5,7,9]. However, because the 
DAS28 is an “ordinal score” (all degrees are not equal), it 
would be methodologically incorrect to calculate cost-
effectiveness ratios such as "cost per unit of DAS28" or "cost 
per unit of HAQ", even though such approaches using the 
HAQ have already been published [16]. Using a 
dichotomous approach (success/no-success =remission/no 
remission or LDAS/no LDAS) of the DAS28 score appeared 
more clinically meaningful for the purpose of this study as 
achieving a remission is the ultimate goal of treating RA. As 
both the DAS28 and HAQ scales are "ordinal" and not 
"cardinal" (all degrees are equal), not only effectiveness 
criteria expressed in "achieving remission" or "achieving 
LDAS" are clinically meaningful, but cost-effectiveness 
calculations also require fewer assumptions. This is also why 
such approaches appear more methodologically robust, as 
already published in Canada by Russel et al., [4], in France 
by Saraux et al., [12], in Italy by Cimmino et al., [13] and in 
Spain by Beresniak et al., [14]. 
  If designed and performed correctly, simulation models 
allow to assess and compare the potential benefits of 
different sequential strategies, and to select those that appear 
the most cost-effective and beneficial to patients. The 
advantages of modelling approaches are especially salient in 
chronic progressive diseases where most health gains and 
any potential economic benefits of different treatments often 
become evident only in the long-term, which typically goes 
far beyond the scope of most clinical trials. 
  Concerning this model’s assumptions and limitations, 
biologic treatments switches were allowed after 6-month 
intervals in case of insufficient response. While treatment 
switches may occur sooner in medical practice, this 
assumption was endorsed due to the fact that most clinical 
trials report effectiveness data at 6 months time points. 
Furthermore, the model considers that RTX potential re-
treatments occur at 6-month intervals because only 6 months 
time points were reported in the publications at the time of 
model development [9]. This assumption does however 
imply a sustained efficacy for RTX over time, and thus, does 
not take into account the potential observed “flares” which 
may occur beyond that time point. While this assumption for 
RTX could be seen as overestimating the actual efficacy of 
RTX when compared with similar sequences including 
ABA, assuming RTX re-treatments at 9 months (instead of 6 
months) would actually not significantly impact the model 
results. This is because this would concern only very few 
patients in the final branches of the model. Furthermore, the 
model did not assess the switch of one anti-TNF agent with 
another anti-TNF agent because anti-TNF "cycling" is not a 
current practice in Finland, and published scientific evidence 
shows that an insufficient response due to a loss of efficacy 
to a first anti-TNF agent is likely to lead to a similar 
response to a 2nd and 3rd anti-TNF agent (which is also 
referred to as a “class effect” because of their similar 
mechanism of action). Hence, Cost-effectiveness of 
treatment sequences using up to 2 and 3 anti-TNF agents 
successively were assessed in France, Spain and Italy [12-
14] and did not show any significant clinical improvement. 
  Finally, the model assumes that a potential remission or 
LDAS are be sustained over the 6-month treatment interval. 
This assumption was deemed appropriate by the expert panel 
at it appears to be consistent with the medical practices in 
Finland. In addition, as the time horizon of the model is 
limited to 2 years, this allows to include published clinical 
evidence from randomized clinical trials. Hence, as no long 
term effectiveness assumptions had to be made compared to 
published lifetime cost-effectiveness models in RA [17], this 
represents a significant advantage as it reduces the 
uncertainty of long-term assumptions. And while the 
relationship between DAS scores and costs is well 
established, it is worth noting that the DAS does not capture 
all aspects of Quality of Life (QOL) improvement, which 
Fig. (1). Exemple of sequence A model structure with remission as effectiveness endpoint. 42   The Open Rheumatology Journal, 2012, Volume 6  Puolakka et al. 
should be considered separately to their full merit. 
Furthermore, as it is not the purpose of one clinical indicator 
to capture all dimensions of life, QOL dimensions should be 
collected separately using appropriate validated instruments. 
  Regarding the optimal criterion for cost-effectiveness 
assessments in RA, this has been a subject of debate and has 
even resulted in misleading use of concepts. Many published 
“cost-effectiveness” models are in fact cost-utility models, 
using “Quality Adjusted Life Years” (QALY) as subjective 
outcome measure [15,18-20]. The QALY method has received 
criticism, not only because different utility instruments (such 
as HUI, EQ5D or SF-6D questionnaires) generate statistically 
divergent utility scores in the same RA population, but 
because they can also lead to widely different cost-utility 
ratios [21-24]. This is raising much ethical questions, which 
also explains why the cost-utility (QALY ) approach is now 
banned from key countries such as USA, Germany and France 
[25]. For these reasons, real cost-effectiveness analyses based 
on “clinically meaningful outcomes” are increasingly 
recommended for being methodologically more transparent, 
consistent and reliable for assessing novel treatments [15] and 
to support health care decision making [22]. In addition, it is 
worth noting that no significant relationship has been 
established between DAS and survival rates [26], as most 
clinical trials do not contain adequate power or follow up to 
differentiate mortality benefits in RA with one intervention 
versus another. This explains why most economic models 
have not included mortality as a treatment-specific 
consequences [3,27]. Because patient registries are not 
designed to allow any treatment comparisons, but to assess 
resource utilization and medical practices, effectiveness data 
reported in registries were not taken into account in order to 
avoid potential selection bias. The present results are based on 
published clinical data and should be updated accordingly 
with upcoming clinical evidence. Economic analyses in RA 
should also ideally consider total direct and indirect costs 
associated with the disease [28]. Since the costs are calculated 
from the public payer perspective, indirect costs, such as 
patient's workability, were not considered in the model. Given 
that RA indirect costs are considerable (i.e., loss of income 
due to lost work days, change in employment or salary, 
productivity loss, long-term disability), the overall cost-
effectiveness and value of different biological strategies is 
likely understated. 
CONCLUSION 
  In summary, RS and LDAS are associated with lower 
medical costs compared to MHDAS. The results of this 
simulation model based on these published clinical outcomes 
suggest that treatment sequences of biologic agents including 
ABA as second biologic option are more efficacious and 
cost-effective than similar sequences including RTX in 
patients with moderate or severe RA and with an insufficient 
response to a first anti-TNF agent 
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